Retinoblastoma is a rare type of cancer that affects one out of every 18000 youngsters; however, it is the most prevalent primary intraocular tumor in adolescents, accounting for 3% of all juvenile cancer cases. After uveal melanoma, it is the second-highest common intraocular malignant cancer.
Survival rates in specialized treatment centers can reach ninety-five percent, with most patients retaining their vision, but they are lower in underdeveloped countries. Retinoblasts are the cells that make up retinoblastoma (scanty cytoplasm and basophilic cells containing hyperchromatic nuclei).
The majority of retinoblastomas are unclassified, although due to the creation of structures known as rosettes, variable levels of differentiation are present. The tumor might be endophytic (in the vitreous) with cancer cells spreading all across the eye, exophytic (in the subretinal region), or have a heterogeneous appearance.
When a tumor extends into the brain and subarachnoid space, it can cause optic nerve invasion. The metastatic spread affects the lungs, local lymph nodes, brain, liver, and bones.
Epidemiology
Retinoblastomas are the most prevalent primary intraocular cancer in children, accounting for three percent of all malignancies in this age group. It’s also the second-highest frequent malignant tumor in the eye. Retinoblastoma affects 1 in every 14000 to 1 in every 20000 births. Every year, 300 new cases are reported in the United States.
Retinoblastoma affects both men and women equally and has no sexual inclination. 90 percent of instances appear before the child reaches the age of three. The disease has a variable prevalence in different parts of the world. Research shows four cases per million in the US and six cases per million in Mexico. The countries with the highest rates include India and Africa.
Anatomy
Pathophysiology
The photoreceptor components of the inside layer of the retina give rise to retinoblastoma. Retinoblastomas are soft and brittle under the microscope and tend to overrun the blood supply, resulting in calcification and necrosis. Dissemination inside the retina and vitreous in the form of tiny, white nodules is prevalent due to its friability.
The appearance of retinoblastomas relies on the level of differentiation under the microscope. Small, spherical, closely packed cells with hyperchromatic nuclei and minimal cytoplasm make up undifferentiated retinoblastoma.
The Homer-Wright rosettes, which are mostly seen in other neuroblastic cancer such as medulloblastoma and neuroblastoma and infrequently seen in retinoblastomas; the Flexner-Wintersteiner rosettes, which are specific for retinoblastomas and seen in seventy percent of neoplasms; and the fleurettes, which are highly characteristic of well-differentiated cancers, have all been described.
Retinoblastoma spreads by a variety of mechanisms. Choroidal invasion opens a vast vascular network, which can act as a conduit for distant metastases. In advanced patients, the tumor extends directly into the orbit via the sclera. Retinoblastoma can spread to the local lymph nodes after invading the iris and ciliary body. Finally, retinoblastomas can invade the cerebral cavity and subarachnoid space by extending along the optic nerve.
Etiology
Retinoblastoma is caused by a mutation in the RB1 cancer suppressor genome, located at locus 14 on the long arm of chromosome 13 at (13q14). A tumor is formed when both copies of the Retinoblastoma 1 gene are altered. There is a 98 percent chance that the mutation in bilateral retinoblastomas is germline.
About five percent of retinoblastoma cases have a hereditary background. Retinoblastoma is spontaneous in 95% of instances, with sixty percent of patients having unilateral disease with a zero-linked genetic mutation. The remainder of the individuals have germline mutations and have developed numerous malignancies.
Heritable
All body cells in this kind of retinoblastoma have an alteration in one of the genes of, the RB1 gene. The malignant transformation of cells occurs when the other allele is mutated because of a mutagenic event. Most of these youngsters develop multifocal retinoblastoma and bilateral because of the mutation in all cells.
Nonocular cancers such as osteosarcoma, pineoblastoma, melanomas, and soft tissue sarcomas are common among heritable illness patients, and these cancers frequently arise in a specific age group. The probability of a second neoplasm is six percent, but it raises 5-fold when the initial tumor is treated with external radiation.
Non-Heritable
Retinoblastomas that are not heritable are unilateral and do not spread. Non-ocular malignancies are not a concern in these groups. It is non-heritable retinoblastomas in the case of unilateral retinoblastoma with negative family background, and the corresponding changes in each patient’s offspring and sibling are one percent. Nonhereditary retinoblastomas account for over ninety percent of unilateral retinoblastoma.
Genetics
Prognostic Factors
Patients with intraocular retinoblastomas, especially those with access to contemporary health care, have a good overall survival rate and prognosis of more than ninety-five percent of developed nations.
Extraocular extension, either through the optic nerve invasion or sclera, is the most crucial risk factor linked with a poor prognosis. Patients who survive bilateral retinoblastomas are more likely to acquire nonocular tumors later in life.
The latent period for the formation of the second tumor is typically nine months. In the first 30 years of life, external beam radiation shortens the inactive period and raises the chance of second cancer. Sarcoma is the most common type of the second neoplasm. Patients who develop sarcoma have a survival rate of fewer than 50%.
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
Media Gallary
References
https://www.ncbi.nlm.nih.gov/books/NBK545276/
https://www.ncbi.nlm.nih.gov/books/NBK13830/
News
Octopus-Inspired Patches Might Be A Pain-Free Alternative to Injections
Posted on
News
Feminist Cancer Care Approach Aims to Save 800,000 Lives Annually
Posted on
News
Breast Lifts Soar in Popularity Among Women
Posted on
News
Researchers Raise Concern on Alcohol Promotion in Sports
Retinoblastoma is a rare type of cancer that affects one out of every 18000 youngsters; however, it is the most prevalent primary intraocular tumor in adolescents, accounting for 3% of all juvenile cancer cases. After uveal melanoma, it is the second-highest common intraocular malignant cancer.
Survival rates in specialized treatment centers can reach ninety-five percent, with most patients retaining their vision, but they are lower in underdeveloped countries. Retinoblasts are the cells that make up retinoblastoma (scanty cytoplasm and basophilic cells containing hyperchromatic nuclei).
The majority of retinoblastomas are unclassified, although due to the creation of structures known as rosettes, variable levels of differentiation are present. The tumor might be endophytic (in the vitreous) with cancer cells spreading all across the eye, exophytic (in the subretinal region), or have a heterogeneous appearance.
When a tumor extends into the brain and subarachnoid space, it can cause optic nerve invasion. The metastatic spread affects the lungs, local lymph nodes, brain, liver, and bones.
Retinoblastomas are the most prevalent primary intraocular cancer in children, accounting for three percent of all malignancies in this age group. It’s also the second-highest frequent malignant tumor in the eye. Retinoblastoma affects 1 in every 14000 to 1 in every 20000 births. Every year, 300 new cases are reported in the United States.
Retinoblastoma affects both men and women equally and has no sexual inclination. 90 percent of instances appear before the child reaches the age of three. The disease has a variable prevalence in different parts of the world. Research shows four cases per million in the US and six cases per million in Mexico. The countries with the highest rates include India and Africa.
The photoreceptor components of the inside layer of the retina give rise to retinoblastoma. Retinoblastomas are soft and brittle under the microscope and tend to overrun the blood supply, resulting in calcification and necrosis. Dissemination inside the retina and vitreous in the form of tiny, white nodules is prevalent due to its friability.
The appearance of retinoblastomas relies on the level of differentiation under the microscope. Small, spherical, closely packed cells with hyperchromatic nuclei and minimal cytoplasm make up undifferentiated retinoblastoma.
The Homer-Wright rosettes, which are mostly seen in other neuroblastic cancer such as medulloblastoma and neuroblastoma and infrequently seen in retinoblastomas; the Flexner-Wintersteiner rosettes, which are specific for retinoblastomas and seen in seventy percent of neoplasms; and the fleurettes, which are highly characteristic of well-differentiated cancers, have all been described.
Retinoblastoma spreads by a variety of mechanisms. Choroidal invasion opens a vast vascular network, which can act as a conduit for distant metastases. In advanced patients, the tumor extends directly into the orbit via the sclera. Retinoblastoma can spread to the local lymph nodes after invading the iris and ciliary body. Finally, retinoblastomas can invade the cerebral cavity and subarachnoid space by extending along the optic nerve.
Retinoblastoma is caused by a mutation in the RB1 cancer suppressor genome, located at locus 14 on the long arm of chromosome 13 at (13q14). A tumor is formed when both copies of the Retinoblastoma 1 gene are altered. There is a 98 percent chance that the mutation in bilateral retinoblastomas is germline.
About five percent of retinoblastoma cases have a hereditary background. Retinoblastoma is spontaneous in 95% of instances, with sixty percent of patients having unilateral disease with a zero-linked genetic mutation. The remainder of the individuals have germline mutations and have developed numerous malignancies.
Heritable
All body cells in this kind of retinoblastoma have an alteration in one of the genes of, the RB1 gene. The malignant transformation of cells occurs when the other allele is mutated because of a mutagenic event. Most of these youngsters develop multifocal retinoblastoma and bilateral because of the mutation in all cells.
Nonocular cancers such as osteosarcoma, pineoblastoma, melanomas, and soft tissue sarcomas are common among heritable illness patients, and these cancers frequently arise in a specific age group. The probability of a second neoplasm is six percent, but it raises 5-fold when the initial tumor is treated with external radiation.
Non-Heritable
Retinoblastomas that are not heritable are unilateral and do not spread. Non-ocular malignancies are not a concern in these groups. It is non-heritable retinoblastomas in the case of unilateral retinoblastoma with negative family background, and the corresponding changes in each patient’s offspring and sibling are one percent. Nonhereditary retinoblastomas account for over ninety percent of unilateral retinoblastoma.
Patients with intraocular retinoblastomas, especially those with access to contemporary health care, have a good overall survival rate and prognosis of more than ninety-five percent of developed nations.
Extraocular extension, either through the optic nerve invasion or sclera, is the most crucial risk factor linked with a poor prognosis. Patients who survive bilateral retinoblastomas are more likely to acquire nonocular tumors later in life.
The latent period for the formation of the second tumor is typically nine months. In the first 30 years of life, external beam radiation shortens the inactive period and raises the chance of second cancer. Sarcoma is the most common type of the second neoplasm. Patients who develop sarcoma have a survival rate of fewer than 50%.
https://www.ncbi.nlm.nih.gov/books/NBK545276/
https://www.ncbi.nlm.nih.gov/books/NBK13830/
medtigo
Retinoblastoma
Updated :
June 16, 2022
Retinoblastoma is a rare type of cancer that affects one out of every 18000 youngsters; however, it is the most prevalent primary intraocular tumor in adolescents, accounting for 3% of all juvenile cancer cases. After uveal melanoma, it is the second-highest common intraocular malignant cancer.
Survival rates in specialized treatment centers can reach ninety-five percent, with most patients retaining their vision, but they are lower in underdeveloped countries. Retinoblasts are the cells that make up retinoblastoma (scanty cytoplasm and basophilic cells containing hyperchromatic nuclei).
The majority of retinoblastomas are unclassified, although due to the creation of structures known as rosettes, variable levels of differentiation are present. The tumor might be endophytic (in the vitreous) with cancer cells spreading all across the eye, exophytic (in the subretinal region), or have a heterogeneous appearance.
When a tumor extends into the brain and subarachnoid space, it can cause optic nerve invasion. The metastatic spread affects the lungs, local lymph nodes, brain, liver, and bones.
Retinoblastomas are the most prevalent primary intraocular cancer in children, accounting for three percent of all malignancies in this age group. It’s also the second-highest frequent malignant tumor in the eye. Retinoblastoma affects 1 in every 14000 to 1 in every 20000 births. Every year, 300 new cases are reported in the United States.
Retinoblastoma affects both men and women equally and has no sexual inclination. 90 percent of instances appear before the child reaches the age of three. The disease has a variable prevalence in different parts of the world. Research shows four cases per million in the US and six cases per million in Mexico. The countries with the highest rates include India and Africa.
The photoreceptor components of the inside layer of the retina give rise to retinoblastoma. Retinoblastomas are soft and brittle under the microscope and tend to overrun the blood supply, resulting in calcification and necrosis. Dissemination inside the retina and vitreous in the form of tiny, white nodules is prevalent due to its friability.
The appearance of retinoblastomas relies on the level of differentiation under the microscope. Small, spherical, closely packed cells with hyperchromatic nuclei and minimal cytoplasm make up undifferentiated retinoblastoma.
The Homer-Wright rosettes, which are mostly seen in other neuroblastic cancer such as medulloblastoma and neuroblastoma and infrequently seen in retinoblastomas; the Flexner-Wintersteiner rosettes, which are specific for retinoblastomas and seen in seventy percent of neoplasms; and the fleurettes, which are highly characteristic of well-differentiated cancers, have all been described.
Retinoblastoma spreads by a variety of mechanisms. Choroidal invasion opens a vast vascular network, which can act as a conduit for distant metastases. In advanced patients, the tumor extends directly into the orbit via the sclera. Retinoblastoma can spread to the local lymph nodes after invading the iris and ciliary body. Finally, retinoblastomas can invade the cerebral cavity and subarachnoid space by extending along the optic nerve.
Retinoblastoma is caused by a mutation in the RB1 cancer suppressor genome, located at locus 14 on the long arm of chromosome 13 at (13q14). A tumor is formed when both copies of the Retinoblastoma 1 gene are altered. There is a 98 percent chance that the mutation in bilateral retinoblastomas is germline.
About five percent of retinoblastoma cases have a hereditary background. Retinoblastoma is spontaneous in 95% of instances, with sixty percent of patients having unilateral disease with a zero-linked genetic mutation. The remainder of the individuals have germline mutations and have developed numerous malignancies.
Heritable
All body cells in this kind of retinoblastoma have an alteration in one of the genes of, the RB1 gene. The malignant transformation of cells occurs when the other allele is mutated because of a mutagenic event. Most of these youngsters develop multifocal retinoblastoma and bilateral because of the mutation in all cells.
Nonocular cancers such as osteosarcoma, pineoblastoma, melanomas, and soft tissue sarcomas are common among heritable illness patients, and these cancers frequently arise in a specific age group. The probability of a second neoplasm is six percent, but it raises 5-fold when the initial tumor is treated with external radiation.
Non-Heritable
Retinoblastomas that are not heritable are unilateral and do not spread. Non-ocular malignancies are not a concern in these groups. It is non-heritable retinoblastomas in the case of unilateral retinoblastoma with negative family background, and the corresponding changes in each patient’s offspring and sibling are one percent. Nonhereditary retinoblastomas account for over ninety percent of unilateral retinoblastoma.
Patients with intraocular retinoblastomas, especially those with access to contemporary health care, have a good overall survival rate and prognosis of more than ninety-five percent of developed nations.
Extraocular extension, either through the optic nerve invasion or sclera, is the most crucial risk factor linked with a poor prognosis. Patients who survive bilateral retinoblastomas are more likely to acquire nonocular tumors later in life.
The latent period for the formation of the second tumor is typically nine months. In the first 30 years of life, external beam radiation shortens the inactive period and raises the chance of second cancer. Sarcoma is the most common type of the second neoplasm. Patients who develop sarcoma have a survival rate of fewer than 50%.
https://www.ncbi.nlm.nih.gov/books/NBK545276/
https://www.ncbi.nlm.nih.gov/books/NBK13830/
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
